Janssen Research & Development LLC, of Titusville, N.J., part of Johnson & Johnson, said three-month paliperidone palmitate (Invega Sustenna), its atypical antipsychotic candidate, significantly delayed time to relapse compared to placebo in patients with schizophrenia, according to phase III findings published in the Journal of the American Medical Association Psychiatry.